Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720629 · OUTCOME

Pharmacodynamics of Visilizumab - Test 1

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation · Source last updated 2014-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
At 1 - 2 hours

What was measured

Mean Cmax (±SD)

Analysis population: All participants

Groups in this outcome

First Study Stage: Study Treatment

Visilizumab, Tacrolimus and Methotrexate. All participants.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
First Study Stage: Study Treatment8

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
First Study Stage: Study Treatment1564428Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        428
        value
        1564
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Mean Cmax (±SD)
dispersion Type
Standard Deviation
groups
  1. description
    Visilizumab, Tacrolimus and Methotrexate. All participants.
    id
    OG000
    title
    First Study Stage: Study Treatment
param Type
MEAN
population Description
All participants
reporting Status
POSTED
time Frame
At 1 - 2 hours
title
Pharmacodynamics of Visilizumab - Test 1
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice